Healthcare - Today Stories

More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK) The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PAD ABBOTT PARK, Ill., April 29, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep a…

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery More than 1.6 million people in the U.S. are affected by tricuspid regurgitation,1 which can severely impact quality of life Data from the TRILUMINATE™ Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits sustained at one year ABBOTT PARK, Ill., April 2, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgit…

First established in 2021, Abbott will continue as Global Health Sciences and Nutrition Partner of the Real Madrid Football Club and Global Partner of the Real Madrid Foundation through the club's 2026-2027 season Partnership aims to reduce childhood malnutrition and promote healthy habits for future generations Abbott has provided over 25,000 hours of nutrition education and screened over 3,000 children for malnutrition since the start of the partnership ABBOTT PARK, Ill. and MADRID, March 4, 2024— Abbott, Real Madrid and the Real Madrid Foundation announced today the extension of their partnership through Real Madrid's 2026-27 season. Abbott will remain Global Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation. Abbott and…

Today is Rare Disease Day, the official international awareness-raising campaign for rare diseases, observed annually on the last day of February. The primary goal of this campaign is to raise awareness among the general public and decision-makers about rare diseases and their influence on the lives of families living with these conditions. Rare Disease Day was launched by EURORDIS-Rare Diseases Europe and its Council of National Alliances in 2008. Did you know: 300 million people worldwide live with a rare disease There are over 6,000 different rare diseases 72% of rare diseases are genetic 70% of these genetic rare diseases begin in childhood. In total, there are around 300 million people worldwide living with a rare disease. Find out more about Rare Disease Day 2024: https://www.rared…

New data supports the potential role of Artificial Intelligence (AI) in predicting patients’ response to immunotherapies in advance of their treatment. AI models demonstrated 70 to 80 percent accuracy in predicting both the likelihood of efficacious response and specific immune-related toxicities. Enables clinicians to match patients to the most effective treatment sooner, potentially avoiding unnecessary side effects and cost, and driving personalized and precise care. CHALFONT ST GILES, England--(BUSINESS WIRE)--GE HealthCare’s Artificial Intelligence (AI) models predict patient response to immunotherapies with 70 to 80 percent accuracy1, based on a pan-cancer cohort, according to findings to be presented at the Society for Immunotherapy of Cancer (SITC) in San Diego, U.S., by GE Healt…

HeartMates will create a supportive and empowering community for people impacted by heart conditions, leveraging Abbott's leadership in cardiovascular care Professional football player and heart health advocate Damar Hamlin joins Abbott to kick off the HeartMates program Heart disease impacts over 100 million Americans, nearly half of U.S. adults1 Abbott will host a media conference call on Tuesday, Oct. 31, at 5 p.m. ET with Hamlin to discuss the program ABBOTT PARK, Ill., Oct. 31, 2023 /PRNewswire/ -- Abbott (NYSE: ABT), a global leader in heart health, announced today the Abbott HeartMates program, a new initiative that will kick off with professional football player Damar Hamlin as its first ambassador.   Experiencing a major heart-related incident can cause emotional distress and be…

Partnership with HealthyWomen and actor, mother and business owner Nicole Ari Parker encourages people to get informed about the importance of COVID vaccination and vaccine options  The Choose to Protect survey, conducted by The Harris Poll, found 85% of U.S. adults aged 45+ agree it is important to have a range of COVID vaccine options for themselves and their family1 Only two in five survey respondents say they are highly knowledgeable about the science behind different types of COVID vaccines1 GAITHERSBURG, Md., Oct. 10, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it has joined forces with HealthyWomen and actor, mother and business owner Nicole Ari Parker to launch Choose to Pr…

GRAND RAPIDS, Mich.--(BUSINESS WIRE)--AirLife, a leading North American manufacturer and distributor of consumable medical devices for anesthesia and respiratory care formerly known as SunMed, today announced the completion of its acquisition of Avanos Medical, Inc.’s (NYSE: AVNS) (“Avanos”) respiratory health business, including the BALLARD*, MICROCUFF* and endOclear® product lines. The acquisition adds three complementary brands, the R&D expertise behind them and two manufacturing facilities into AirLife’s growing platform. The transaction advances AirLife’s strategy to enhance its leading portfolio of the most trusted products in anesthesia and respiratory care and serve even more customers as a one-stop source for the highest-quality consumable breathing solutions that support the…

94% of Advanced Practice Providers (APPs) believe more educational resources about the rare blood cancer multiple myeloma could help improve the patient experience HORSHAM, Pa., September 26, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with the Advanced Practitioner Society for Hematology and Oncology (APSHO), today announced the launch of Make It HAPPen™, a multi-year effort designed to recognize and support Advanced Practice Providers (APPs) in the life-changing care they provide to people living with multiple myeloma. The campaign launched in response to a recent national survey, which showed that, among people who are living with multiple myeloma, most (93%) viewed APPs as essential to their care, and more than half (61%) felt they could ask t…

Brand and visual identity demonstrate the best of Johnson & Johnson’s care and humanity, while capturing the Company’s passion and determination to improve the health of people worldwide New Brunswick, N.J., Sept. 14, 2023 – For more than 135 years, Johnson & Johnson (the “Company”) (NYSE: JNJ) has provided health care products and solutions to people worldwide. Now, with its exclusive focus on healthcare innovation and tackling the toughest health challenges, the Company is updating its brand and uniting both its medtech and pharmaceutical segments under the Johnson & Johnson brand name to demonstrate its collective power in healthcare. The announcement marks the next era for Johnson & Johnson, which is leveraging its expertise in innovative medicine and medical tech…

Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that turn data from a continuous glucose monitor (CGM) into clear and reliable insulin dosing recommendations displayed right on the insulin pen cap Acquisition will bring together two leaders in different aspects of diabetes care: CGM and insulin injection support Together, Abbott and Bigfoot will continue to advance technology-driven solutions for making diabetes management even more personal and precise ABBOTT PARK, Ill. and MILPITAS, Calif., Sept. 5, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Bigfoot Biomedical today announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people…

Abbott's breakthrough technology enables the world's first beat-to-beat, wireless communication and synchronization between two leadless pacemakers, which are smaller than a AAA battery Leadless pacemakers provide a new minimally invasive option that will revolutionize care for more people in the U.S. who need pacing to treat a variety of slow or abnormal heart rhythms Approval comes on the heels of recent late-breaking clinical trial data showing that the AVEIR™ DR leadless pacemaker system is safe and effective at treating abnormal heart rhythms ABBOTT PARK, Ill., July 5, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pac…

GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the “Arrangement”). The Arrangement was approved by BELLUS’ shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC. In connection with the closing of the Arrangement, BELLUS also announced the cancellation of its annual shareholder meeting, which was sc…

Sanofi Consumer Healthcare launches new portal to unlock science and solve key challenges in self-care Paris, France – June 14, 2023 – Sanofi’s Consumer Healthcare Business Unit has today launched a new Open Innovation Portal, allowing the wider supply chain community to submit their creative, disruptive, and game-changing solutions to meet the challenges of an ever-evolving consumer healthcare landscape. Startups, entrepreneurs, research institutions, accelerators, universities and more can now respond online to challenge areas that have been identified by Sanofi Consumer Healthcare, from creating sustainable packaging to developing new products and technologies. The healthcare landscape is evolving rapidly and, post-COVID, with an ever-increasing recognition of the importance of self-car…

Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker The study successfully met all three of its primary safety and performance endpoints Abbott's investigational AVEIR DR leadless pacemakers have been submitted for evaluation by the U.S. FDA NEW ORLEANS, May 20, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to assess the world's first dual-chamber leadless pacemaker, showing that the leadless pacemaker met its three prespecified primary endpoints for safety and performance. The data further suggests that AVEIR DR could offer new benefits for people…

New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation The new programs build on a successful first year of the multi-million-dollar corporate initiative ABBOTT PARK, Ill., May 11, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on…

Abbott's CentriMag™ Blood Pump, previously cleared for use up to six hours, now can be used to provide longer-term life support to critically ill patients, providing doctors more time to make critical care decisions Abbott's CentriMag™ Pre-connected Pack, which combines a blood pump and oxygenator to form a life support circuit, also received FDA clearance for life support lasting less than six hours, helping physicians provide urgent critical care more efficiently and in fewer steps ABBOTT PARK, Ill., April 25, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system. With the new indication, the CentriMag Blood Pump for use with the CentriMag™ System, is now cleared…

A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its recently appointed Impact Council In three years' time, Gilde Healthcare raised over €1.5 billion across three funds UTRECHT, Netherlands, April 19, 2023 /PRNewswire/ -- Gilde Healthcare today announces a new investment fund with €600 million in commitments: Gilde Healthcare Venture&Growth VI. The new fund focuses on fast growing companies developing solutions for better care at lower cost. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, medical technology (MedTech) and therapeutics. The fund is…

Today marks World Health Day, as well as the World Health Organization’s 75th birthday. This year’s theme is ‘Health For All’ – a theme envisioning that all people have good health for a fulfilling life in a peaceful, prosperous, and sustainable world. The right to health is a basic human right. Everyone must have access to the health services they need when and where they need them without financial hardship. Did you know: 30% of the global population is not able to access essential health services Almost two billion people face catastrophic or impoverishing health spending, with significant inequalities affecting those in the most vulnerable settings Between 2023-2030 there is a projected shortfall of 10 million health workers worldwide Find out more about World Health Day 2023, and th…

New, independent kidney health technology company will combine expertise from two industry leaders to drive care transformation DUBLIN and DENVER, April 1, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT) and DaVita Inc. (NYSE: DVA) today announced the launch of Mozarc Medical—an independent new company committed to reshaping kidney health and driving patient-centered technology solutions. "Mozarc Medical's focus will be on meaningful and innovative kidney health technologies that improve the overall patient experience and increase access to care globally," said Ven Manda, CEO of Mozarc Medical. "At a time when patient preferences are evolving and in-home kidney care is on the rise, Mozarc Medical is uniquely positioned to better serve patients with kidney disease around the world." Central…